Table 5 p53 status and prognosis of colorectal cancer: comparison between literature deta and the present report
Reference | n | Histology treatment | Methods for determing p53 Ab | IHC | Sequencing | Frequency of alterd p53 pathway (%) | Prognostic value | Event-free survival | Response | |
|---|---|---|---|---|---|---|---|---|---|---|
Overall survial | ||||||||||
Popat S [22] | 967 | CRC | Adjuvant | - | + | - | 60 (IHC) | NS | NA | NA |
Zaana A [23] | 233 | CRC | Adjuvant | - | + | - | 53 (IHC) | NA | NS | NA |
Ahn MJ [24] | 45 | mCRC | chemotherapy | - | + | - | 80 (IHC) | NA | NA | NS |
Berglund A [25] | 122 | mCRC | chemotherapy | - | + | - | 60 (IHC) | NS | NA | NS |
Ince WL [26] | 295 | CRC | chemotherapy | - | + | + | 68 (IHC), 72(S) | NS, NS | NA | NA |
Mollevi DG [27] | 91 | mCRC | chemotherapy | - | - | + | 50.5 (S) | multivariate | NA | NA |
Rosty C [28] | 56 | mCRC | chemotherapy | - | - | + | 62.5 (S) | univariate | NA | NS |
Westra JL [29] | 220 | CRC | Adjuvant | - | - | + | 53(S) | NA | murtivariate | NA |
Oden-Gangloff [30] | 64 | mCRC | chemotherapy | - | - | + | 64(S) | NA | murtivariate | NA |
Present study | 90 | mCRC | chemotharapy | + | + | - | 40(Ab), 63(IHC) | NS,NS | NS,NS | NS,NS |